Background: Hyperbaric oxygen (HBO) inhibits ischemia reperfusion (IR) -induced neutrophil adhesion to endothelium through an unknown mechanism. This study evaluates the effect of HBO on IR-stimulated neutrophil adhesion and polarization of expressed CD18 adhesion molecules using a novel in vitro adhesion assay and confocal microscopy.
Materials And Methods: Neutrophils from normal animals were isolated from whole blood and incubated with plasma from rat gracilis muscle flaps on coverslips pretreated with ICAM. Percent adherence to ICAM and CD18 polarization was evaluated in the following five groups: (1) Nonischemic control, n = 15; (2) 4 h ischemia (IR, n = 15); (3) 4 h ischemia with HBO treatment (100% oxygen at 2.5 atmospheres absolute (IR + HBO, n = 15)); (4) 4 h ischemia with 100% oxygen at room temperature and pressure (RTP) (IR + normobaric hyperoxia, n = 5); and (5) 4 h ischemia with 8% oxygen at 2.5 atmospheres absolute (IR + hyperbaric normoxia, n = 5). Direct HBO treatment of neutrophils was also evaluated.
Results: Neutrophils exposed to IR plasma showed a significant increase in percent adherent (0.8 +/- 0.1% versus 16.7 +/- 2.2%, P < 0.05) and polarized cells (6.2 +/- 1.7% versus 43.9 +/- 12.2%, P < 0.05) compared to controls. Hyperbaric oxygen significantly reduced the adhesion and polarization to 1.6 +/- 0.3 and 4.1 +/- 2.5%, respectively (P = < 0.05). Normobaric hyperoxia and hyperbaric normoxia did not affect neutrophil adherence or CD18 polarization following IR. Direct HBO treatment of neutrophils did not change the percent of polarized cells in IR.
Conclusions: Hyperbaric oxygen inhibits IR-induced neutrophil adhesion by blocking CD18 surface polarization and requires plasma exposure to HBO. Treatment with oxygen or pressure alone is not effective.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jss.2007.12.780 | DOI Listing |
Gastroenterol Hepatol (N Y)
December 2024
Gastroenterol Hepatol (N Y)
December 2024
DEN Open
April 2025
Department of Gastroenterology, Hematology, and Clinical Immunology Hirosaki University Graduate School of Medicine Aomori Japan.
Severe esophageal strictures resulting from chemoradiotherapy pose persistent therapeutic challenges despite the availability of treatments such as endoscopic balloon dilation and medications. Hyperbaric oxygen therapy (HBOT) has emerged as a promising treatment option for refractory radiation-induced injury to several organs. Herein, we present the case of a 79-year-old male patient with refractory radiation-induced ulcerative esophageal strictures after chemoradiotherapy.
View Article and Find Full Text PDFClin J Pain
January 2025
Department of Anesthesiology and Perioperative Medicine, University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.
Objectives: Complex regional pain syndrome remains a challenging condition characterized by severe, persistent pain and a variety of inflammatory and trophic symptoms. This study aimed to analyze the current literature to evaluate hyperbaric oxygen therapy (HBOT)'s efficacy in treating complex regional pain syndrome (CRPS), focusing on both sympathetically-maintained pain (SMP) and sympathetically-independent pain (SIP) subtypes.
Methods: A comprehensive literature search was conducted in PubMed Clinical Queries using the MeSH term "Complex Regional Pain Syndromes" OR the keyword "CRPS" AND "Hyperbaric Oxygen Therapy" OR the keyword "HBOT".
Syst Rev
January 2025
Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Background: The clinical characteristics, therapy, and outcome of Fournier Gangrene (FG) in patients using sodium-glucose cotransporter-2 inhibitors (SGLT2i) were examined in this systematic review.
Methods: Without a publication year restriction, we searched PubMed, ScienceDirect, and Cochrane. Additionally, we manually searched bibliographies using the terms "Fournier's gangrene" and "SGLT2 inhibitors.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!